[1]杨建华,屈芙蓉,杨建军,等.十味诃子汤散联合恩替卡韦分散片治疗慢性乙型肝炎合并非酒精性脂肪性肝炎疗效研究*[J].陕西中医,2019,(11):1507-1509.
　YANG Jianhua,QU Furong,YANG Jianjun,et al.Observation on the therapeutic effect of Shiwei Hezitang powder combined with entecavir dispersible tablets in treating chronic hepatitis B complicated with nonalcoholic steatohepatitis[J].,2019,(11):1507-1509.
点击复制

十味诃子汤散联合恩替卡韦分散片治疗慢性乙型肝炎合并非酒精性脂肪性肝炎疗效研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年11期
页码:
1507-1509
栏目:
临床研究
出版日期:
2019-11-05

文章信息/Info

Title:
Observation on the therapeutic effect of Shiwei Hezitang powder combined with entecavir dispersible tablets in treating chronic hepatitis B complicated with nonalcoholic steatohepatitis
文章编号:
DOI:10.3969/j.issn.10007369.2019.11.005
作者:
杨建华1; 屈芙蓉1; 杨建军1; 宁博1; 姜凡2△
1.陕西省宝鸡市中心医院感染性疾病科（宝鸡 721008）；2.陕西省宝鸡市中医医院（宝鸡 721001）
Author(s):
YANG Jianhua; QU Furong; YANG Jianjun; et al.
Department of Infectious Diseases,Central Hospital of Baoji in Shaanxi Province(Baoji 721008)
关键词:
慢性乙型肝炎; 非酒精性脂肪性肝炎; 十味诃子汤散; 恩替卡韦分散片; 白蛋白; 血清胆红素
Keywords:
Key words Chronic hepatitis B; Nonalcoholic steatohepatitis; Shiwei Hezitang powder; Entecavir dispersible tablets; Albumin; Serum bilirubin
分类号:
R512.62
文献标志码:
A
摘要:
摘要目的：观察十味诃子汤散联合恩替卡韦分散片治疗慢性乙型肝炎合并非酒精性脂肪性肝炎的临床治疗效果。方法：随机抽取50例慢性乙型肝炎合并非酒精性脂肪性肝炎患者作为本研究观察对象，根据双盲法将全部患者分为对照组和治疗组各25例。对照组患者给予常规恩替卡韦分散片进行治疗，治疗组患者在对照组基础上加用十味诃子汤散进行联合治疗。观察对比两组患者的临床疗效，治疗前后的血清肝功能指标变化，包括白蛋白(ALB)、血清胆红素（TBil）、天门冬氨酸氨基转移酶（AST）和丙氨酸氨基转移酶（ALT）的水平。比较两组患者治疗前后的血脂变化，包括胆固醇(TC)及甘油三酯(TG)的水平。结果：治疗组治疗总有效率显著高于对照组（P＜005）；治疗后，治疗组ALB水平显著高于对照组（P＜005），治疗组ALT、 AST和TBil水平显著低于对照组（P＜005）。治疗后，治疗组TC、TG水平显著低于对照组（P＜005）。结论：十味诃子汤散联合恩替卡韦分散片治疗慢性乙型肝炎合并非酒精性脂肪性肝炎，能提高临床治疗效果，明显改善患者各项血清肝功能指标，降低患者血脂水平，且临床不良反应发生率低。
Abstract:
AbstractObjective:To observe the clinical therapeutic effect of Shiwei Hezitang powder combined with entecavir dispersible tablets in the treatment of chronic hepatitis B complicated with nonalcoholic steatohepatitis.Methods:A total of 50 patients with chronic hepatitis B and nonalcoholic steatohepatitis were randomly divided into control group (n=25) and treatment group (n=25) according to doubleblind method.Among them,the patients in the control group were treated with Entecavir dispersible tablets,while the patients in the treatment group were treated with Shiwei Hezitang powder on the basis of the treatment in the control group.To observe and compare the clinical efficacy of the two groups,the changes of serum liver function indexes before and after treatment,including the levels of albumin (ALB),serum bilirubin (TBil),aspartate aminotransferase (AST) and alanine aminotransferase (ALT).The changes of blood lipids,including cholesterol (TC) and triglyceride (TG),were compared between the two groups before and after treatment.Results:The total effective rate of the treatment group was significantly higher than that in the control group (P＜005);after treatment,the level of ALB in the treatment group was significantly higher than that in the control group (P＜005),and the levels of ALT,AST and TBIL in the treatment group were significantly lower than those in the control group (P＜005).After treatment,the levels of TC and TG in the treatment group were significantly lower than those in the control group (P＜005).Conclusion:Shiwei Hezitang powder combined with entecavir dispersible tablets in the treatment of chronic hepatitis B complicated with nonalcoholic steatohepatitis can significantly improve the patients'serum liver function indicators,reduce blood lipid levels,and the incidence of clinical adverse reactions is low.

参考文献/References:

[1]王浩.中西医结合治疗慢性乙型肝炎合并非酒精性脂肪性肝炎的临床观察[J].中西医结合肝病杂志,2017,5(3):177178.
[2]汪涛.恩替卡韦联合肝癖Ⅰ号膏方治疗肝郁脾虚痰湿内蕴型慢性乙型肝炎合并非酒精性脂肪肝临床疗效观察[J].广西中医药大学,2017,5(27):226229.
[3]刘璐璐,任艺,何毅怀,等.慢性乙型肝炎合并非酒精性脂肪性肝病的研究进展[J].临床肝胆病杂志,2017,33 (3):538542.
[4]黄娇凤,林苏,王明芳,等.恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响[J].实用肝脏病杂志,2018,3(6):109110.
[5]曹丹,陈文静,李艳平,等.慢性乙型肝炎合并非酒精性脂肪性肝病的临床研究进展[J].临床肝胆病杂志,2018,34(9):19861989.
[6]樊橡伟，胡勃，王向阳.肝苏胶囊联合水飞蓟宾胶囊治疗非酒精性脂肪肝合并慢性乙肝临床研究[J].陕西中医， 2019,40(2)：160162.
[7]张谨,车改云,秦延军,等.新核苷 (酸) 类似物对乙肝患者肝硬化失代偿期的影响分析[J].陕西医学杂志,2016,45(8):10071008.
[8]武钰林,杨慷.乙型肝炎与非酒精性脂肪性肝病的相关性[J].肝脏，2018,23(7):637640.
[9]蒋金艳.恩替卡韦治疗非酒精性脂肪性肝病合并慢性乙型肝炎的疗效及对胰岛素抵抗的影响[J].中国临床新医学,2017,10(7):652654.
[10]姚向波,尹毅,周筱燕.十味诃子汤散联合恩替卡韦治疗老年慢性乙型肝炎合并非酒精性脂肪肝的临床研究[J].现代中药研究与实践,2017,31(6):7276.
[11]张扬,扈晓宇,杨芳.温肾方治疗慢性乙型肝炎合并非酒精性脂肪性肝炎的随机对照临床研究[J].中华中医药杂志,2018,33(5):19751978.
[12]蒋金艳.恩替卡韦治疗非酒精性脂肪性肝病合并慢性乙型肝炎的疗效及对胰岛素抵抗的影响[J].中国临床新医学,2017,10(7):652654.
[13]宁碧泉.黄连温胆汤加味治疗非酒精性脂肪性肝炎（痰热夹瘀证）的临床研究[J].广西中医药大学,2017,34(9):19861989.
[14]张舰琼.慢性HBV感染合并NAFLD炎症病理特征及无创临床模型研究[J].天津医科大学,2017,31(1):172176.
[15]王玉泽,张海丛,叶立红,等.乙肝病毒对脂肪肝患者肝功能及血清肿瘤坏死因子α与白细胞介素6的影响[J].现代中西医结合杂志,2016,25 (6):612614.
[16]孙涛， 杜凤梅， 戴立娟.恩替卡韦治疗对慢性乙型肝炎患者血糖和血脂的影响[J].肝脏，2019,24(6):680.

相似文献/References:

[1]张意兰,冯军安,韩际奥.祛毒退黄汤结肠滴注给药对慢性乙型肝炎肠源性内毒素血症、外周血Th17/Treg细胞因子和肝功能的影响*[J].陕西中医,2019,(1):55.
　ZHANG Yilan,FENG Junan,HAN Jiao..Effect of sputum and phlegmremoving broth in colonic endotoxemia, peripheral blood Th17/Treg cytokines and liver function in patients with chronic he patitis B[J].,2019,(11):55.
[2]田水林,施 琳,施卫兵△.逍遥散联合恩替卡韦治疗肝郁脾虚型慢性乙型肝炎疗效研究*[J].陕西中医,2020,(6):754.[doi:DOI:10.3969/j.issn.10007369.2020.06.015]
　TIAN Shuilin,SHI Lin,SHI Weibing..Study on effect of Xiaoyao powder combined with entecavir on patients with chronic hepatitis B of Ganyu Pixu type[J].,2020,(11):754.[doi:DOI:10.3969/j.issn.10007369.2020.06.015]
[3]蒋淑莲,谭善忠,文 剑.柴芍六君汤治疗慢性乙型肝炎肝纤维化疗效及对患者血清Treg/Th17的影响[J].陕西中医,2021,(9):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]
　JIANG Shulian,TAN Shanzhong,WEN Jian.Therapeutic effect of Chaishao Liujun decoction on hepatic fibrosis in chronic hepatitis B and effect on serum Treg/Th17[J].,2021,(11):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]

备注/Memo

备注/Memo:
*陕西省社会发展科技攻关项目(2015SF068)
更新日期/Last Update: 2019-11-15